GSK noted recent deals as source of fresh revenues amid patent expiries and an AI-driven boost to drug discovery.
Trump says voters won’t fund AI’s power binge, Microsoft says it will pay, and 2026 rate cases will decide who eats the cost ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback